relies on different classes of chemotherapeutic agents. including epipodophyllotoxins. anthracyclines and platinum analogtues. Although the introduction of combination chemotherapy as the principal form of treatment has led to an increase in median sunrival. only a small proportion of patients with SCLC are cured (Souhami and Las-. 1990) .
Mechanisms of drucg resistance in solid tumours haxe been examined extensixel over the last 10 years. In lung cancer cell lines selected in vitro grenetic chanoes have been identified that alter drug transport and activity. such as overexpression of the Pglycoprotein or the multidrug resistance-associated protein (MRP) (Dovle. 1993 : Gonzalez Manzano et al. 1996 : Versantxoort et al. 1996 . However. no correlation between overexpression of these drug transporters in lung, cancer cells and response to therapy has been found in patients (Lai et al. 1989) suggesting that other mechanisms are more important for chnical drug resistance of lung cancer. It is now generally accepted that resistance to cytotoxic treatments relates to failure of cells to engyage the process of apoptosis. and some of the genetic defects that antagonize apoptosis have alreadv been unravelled. Most SCLC cell lines and tumour tissues overexpress the Bcl-2 oncoprotein (Ben Ezra et al.
Modulation of gene expression by antisense oligodeoxynucleotides (ODNs) is a promising approach because of its target specificity and potential applicability to any sequenced gene The mechanisms implicated in the action of antisense ODNs relate to RNase H-mediated hydrolysis of the target mRNA or to translational arrest anrsing from steric hindrance by the RNA-DNA heteroduplex (Stein and Cheng. 1993: Ho and Parkinson. 1997) . These mechanisms differ greatly from those exerted by chemotherapeutic arents and thus might operate also in drum-resistant tumour cells. Antisense ODNs targeting the first six codons of the bcl-2 mRNA have been show-n to increase the sensitivity of lymphoma cells to chemotherapeutic acents (Kitada et al. 1994 ).
However. althouth the combination of bcl-2 antisense ODNs and chemotherapy seems to be appealing. the cytotoxic interaction of these treatments on tumour cells has not yet been addressed in detail. Recently. we has-e identified an antisense sequence (ODN 2009) targeting the bcl-2 coding region that effectixelv downregulated bcl-2 expression and induced apoptosis in SCLC cells (Ziegler et al. 1997) . In the present study. we examined the cytotoxic effects of ODN 2009 in combination with etoposide. doxorubicin and cisplatin on SCLC cell lines with different Bcl-2 levels.
Analysis of potential synergy w-as performed by the median effect method described by Chou and Talalay ( 1984 
Measurement of cell viability
The cytotoxic effects of ODN 2009 and chemotherapeutic agents on SCLC cell lines were determined by use of the colorimetric WST-1Iiabilitx assav as described previously (Ziegler et al. 1997) . Once the optimal growth conditions have been established for each cell line. the WST-1 viabilitv assav provides reproducible results which correlate well with the actual number of X iable cells determined by propidium iodide exclusion (Ziegler et al. 1997 Germanv) was added per well and allowed to react for 3-5 h at 37"C. Absorbance at 450 nm was measured by use of an enzx-melinked immunosorbent assav reader (2550 EIA reader. Bio Rad Laboratories. Hercules. CA. USA).
Determination of viable cell numbers based on propidium iodide exclusion
To determine the number of x-iable cells after cytotoxic treatment. 4 ml of cell suspensions containing ODN 2009. chemotherapeutic agents or a combination of both types of agents were plated in sixwell plates. The same cell densities as for the WST-1 viabilitx assay described above w ere used. At different time points of incubation. cells were harnested. briefly trvpsinized and resuspended in phosphate-buffered saline (PBS). Immediately before measurement. propidium iodide was added to a final concentration of 1.25 jge ml . The number of cells in the cultures w as quantitated at a constant flow rate of 12 ' a mmn-I by use of a FACSCalibur cvtofluorometer (Becton Dickinson. Mountain View. CA. USA). Only' cells that excluded propidium iodide w ere considered Xiable. Apoptotic cell death after cvtotoxic treatment was confirmed by forward and side light scatter analy-sis as described prexviouslV (Cotter et al. 1992 : Ziegler et al. 1997 ).
Analysis of combined ODN/drug effects
The median-effect method described by Chou and Talalay (1984) was used to determine the nature of interaction betxxeen ODN Figure 4A . Compared with the other cell lines used in this study. the NCI-H69 cell line has the highest level of Bc1-2 (Fioure 1. Table 1 Compared with the cell lines SW2 and NCI-H69. the NCI-H82 cell line has barely detectable Bcl-2 levels ( Figure 1 . Table 1 ). The different slopes of the median-effect curves (data not show-n)
suggest that on this cell line all combinations resulted in mutuall1 Combination chemotherapy has become the standard treatment for SCLC (Souhami and Law. 1990 ). The cytotoxic interactions of various chemotherapeutic agents have been analysed in xitro bv different calculation methods (Kaufmann et al. 1996 : Photiou et al. 1997 . and it has been show-n that even clinicallx approved drug combinations may result in less than additive effects (Kaufmann et al. 1996) . These findings imply that such in vitro studies migCht be useful for the selection and design of optimal druga combinations for clinical application. Combinations of antisense ODNs targeting specific oncogenes or gyenes involved in drug, resistance. such as bcl-2. and less toxic doses of chemotherapeutic agents represent a rational therapeutic strategy to pursue. In models of human leukaemia and colon carcinoma xenografts in mice. it has been shown that antisense ODNs targeting the oncogenes berlabl (Skorski et al. 1997) or c-mvb (Del Bufalo et al. 1996) . or the multiple drug resistance gene mdrl (Cucco and Calabretta. 1996) can indeed enhance the anti-tumour effect of chemotherapeutic agents. However. these studies did not directly insvestioate the interaction of the antisense ODNs with chemotherapeutic agents in vitro and did not search for synergistic combinations.
In the present study. (Bennett et al. 1992) .
Although the intracellular targets and the mechanisms of action of ODN 2009 and the chemotherapeutic agents are different. their effects eventually merge in a common final death pathw-ay. In this case. one would expect the interactions between ODN 2009 and etoposide. doxorubicin or cisplatin to be mutually exclusive. For example. Bcl-2 has been shown to inhibit apoptosis induced by etoposide through effects on events early after topoisomerase IIinduced DNA damage (Kamesaki et al. 1993 ). According to Chou and Talalay ( 1984) . agents are claimed to be mutually exclusive if (2) the assumption whether agents act independently or not cannot be made solely based on our current understanding of the initial steps in their mechanisms of action. Considerinc this uncertaintv. in the present study all data were analy-sed assuming both mutually exclusive and non-exclusive interactions of the agents.
In considerinc the potential implication of this study. one limitation must be kept in mind. The data for each cell line were generated using fixed ratios of the agents. If a different ratio had been evaluated. a different CI plot would have resulted. Thus. because the entire response surfaces (Greco et al. 1995) 
